STAT Plus Cancer biotech gets another new name now its called Xilio and more than $100 million

STAT Plus: Cancer biotech gets another new name (now it’s called Xilio) and more than $100 million

Akrevia Therapeutics has changed its name again and raised more than $100 million in additional venture capital.

More From BioPortfolio on "STAT Plus: Cancer biotech gets another new name (now it’s called Xilio) and more than $100 million"